Kura Oncology (KURA) traded up 0.1 % during a 24 hours period ending at 10:19 AM Central Europe on Tuesday 27th. One Kura Oncology stock can currently be bought for about USD 9.62 on popular exchanges. Current supply of Kura Oncology stocks is 89.1 mn. Kura Oncology has a current market capitalization of USD 870.9 mn and approximately USD 8.3 mn worth of Kura Oncology was traded on exchanges in the last 24 hours. Since last month end, Kura Oncology has traded -9.33 % down. Simple moving average of last 200 days is at USD 9.78. The highest price of past 52 weeks was recorded at USD 13.9 on 08/25/2026. 52 weeks low was at USD 7.36 on 02/05/2026.

Here is how related stocks have performed in the past 24 hours:

  • Mannkind (MNKD) traded up 1.25 % and now trades at USD 3.23. Mannkind has a market capitalisation of USD 1 bn.

  • Eagle (EGBN) traded down -1.16 % and now trades at USD 33.29. Eagle has a market capitalisation of USD 1 bn. Eagle has a current price to earnings ratio of 23.7.

  • Capitol Federal (CFFN) traded up 0.48 % and now trades at USD 8.44. Capitol Federal has a market capitalisation of USD 1 bn. Current price/earnings ratio for Capitol Federal is 12.86.

  • Arrivent Biopharma (AVBP) traded down -26.86 % and now trades at USD 15.36. Arrivent Biopharma has a market capitalisation of USD 1 bn. ArriVent BioPharma, Inc. reported early Phase 1 results for its cadherin‑17‑targeting antibody‑drug conjugate ARR‑217, presented at the 2026 European Society for Medical Oncology Congress. The data, shared in a press release filed as an exhibit to its Form 8‑K, highlighted encouraging tumor response rates in heavily pre‑treated gastrointestinal cancer patients, particularly at the 6 mg/kg dose, while noting a manageable safety profile. The company confirmed that ARR‑217 has entered a Phase 1b dose‑optimization study and anticipates additional efficacy and safety data in 2027. The announcement was accompanied by a scheduled webinar to discuss the findings. No material financial information or market‑impact events were disclosed beyond the clinical update.

  • Ceribell (CBLL) traded down -0.37 % and now trades at USD 27.03. Ceribell has a market capitalisation of USD 1 bn.

About Kura Oncology

Kura Oncology, Inc. is a clinical stage biopharmaceutical company based in La Jolla, California. The company specializes in discovering and developing personalized therapeutics for the treatment of tumors and blood cancers. They offer development programs for cancers with high unmet need, including lung, colorectal, thyroid, blood, and pancreatic cancers. You can find more information about their work on their website, www.kuraoncology.com , and they are listed on the Nasdaq stock exchange.